Bristol-Myers Squibb stock heads into the open after a 0.4 percent dip

At the close on September 11, 2026, Bristol-Myers Squibb stock ended at USD 63.52 on the NYSE, down 0.35 percent, while the shares stayed well above their level at the start of the year and offered a near-4 percent dividend yield.

Bristol-Myers Squibb stock closed at USD 63.52 on the New York Stock Exchange on September 11, 2026, slipping 0.35 percent on the day according to MarketBeat data. Per an analysis by Ad-hoc-news, the shares were up about 17.8 percent since the beginning of 2026 as of September 11, 2026, while offering a forward dividend yield of about 3.94 percent based on a share price of USD 63.62.

September 11, 2026 in numbers

Bristol-Myers Squibb Inc. (ISIN US1078421011, NYSE: BMY) saw its stock trade firmly in the mid-60-dollar range on September 11, 2026, with a session high and low around the USD 63 area and a closing price of USD 63.52 on the New York Stock Exchange, according to MarketBeat data. Extended trading after the close showed the shares at USD 63.54 at 7:55 p.m. Eastern on September 11, 2026, signaling only marginal after-hours interest. An overview by Ad-hoc-news highlighted that at this level the stock remained materially above its price at the start of the year, while the company offered a forward annual dividend of USD 2.52 per share, paid in quarterly installments of USD 0.63.

The same analysis cited data from Yahoo Finance indicating a dividend yield of about 3.94 percent based on a share price of USD 63.62 as of September 11, 2026, underscoring the role of income as a component of the total return profile. The article also mentioned a market capitalization near USD 130 billion as of September 12, 2026, showing Bristol-Myers Squibb in the large-cap segment of the US equity market. A discussion of the stock by The Globe and Mail described recent interest from income-oriented investors who focus on the combination of dividend payments and moderate share price appreciation.

Today’s drivers to watch

Looking ahead to today, general macroeconomic releases rather than company-specific events appear set to shape sentiment in the broader pharmaceutical sector. A global economic calendar compiled by Svmuu lists several data points for September 14, 2026, including inflation and activity indicators, which can influence expectations for interest rates and healthcare spending. In addition, a weekly sector report for pharma and biotech issued on September 14, 2026 by OriginBrief notes regulatory and environmental policy developments in Europe that could affect sentiment toward large drug makers, even though Bristol-Myers Squibb’s main listing is in the United States. Against this backdrop, investors will watch how Bristol-Myers Squibb stock trades when US markets open today, with attention on the balance between its dividend appeal and the sector’s response to macro and regulatory headlines.